Edition:
United States

Immune Design Corp (IMDZ.OQ)

IMDZ.OQ on NASDAQ Stock Exchange Global Market

3.70USD
12 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.70
Open
$3.70
Day's High
$3.70
Day's Low
$3.70
Volume
1,842
Avg. Vol
111,618
52-wk High
$13.00
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Ecor1 Capital reports 7.4% passive stake in Immune Design
Monday, 6 Nov 2017 01:47pm EST 

Nov 6 (Reuters) - Ecor1 Capital Llc::Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​.  Full Article

Immune Design reports Q3 loss per share of $0.52
Wednesday, 1 Nov 2017 04:02pm EDT 

Nov 1 (Reuters) - Immune Design Corp -:IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.52.Q3 REVENUE $500,000.Q3 REVENUE VIEW $1.4 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.  Full Article

Immune Design prices offering of 19.5 million shares at $4.10 per share​
Tuesday, 24 Oct 2017 09:16pm EDT 

Oct 24 (Reuters) - Immune Design Corp :Immune Design prices $80.0 million public offering of common stock.Says ‍priced public offering of 19.5 million shares of its common stock at price to public of $4.10 per share​.  Full Article

Immune Design proposes public offering of common stock
Monday, 23 Oct 2017 04:14pm EDT 

Oct 23 (Reuters) - Immune Design Corp :Immune Design announces proposed public offering of common stock.Immune Design Corp - ‍plans to offer and sell up to 16 million shares of its common stock in an underwritten public offering​.Immune Design Corp - ‍net proceeds of offering to fund its Phase 3 clinical trial for CMB305 in synovial sarcoma patients & to continue to develop CA21.  Full Article

Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305
Monday, 16 Oct 2017 04:15pm EDT 

Oct 16 (Reuters) - Immune Design Corp :Immune Design announces positive FDA feedback on Phase 3 clinical trial design for CMB305 in synovial sarcoma patients.Immune Design- plans to initiate pivotal Phase 3 trial to support a Biologics License Application (BLA) for CMB305 in patients with synovial sarcoma​.  Full Article

Immune Design Q2 loss per share $0.54
Wednesday, 2 Aug 2017 04:02pm EDT 

Aug 2 (Reuters) - Immune Design Corp :Immune Design reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.54.Q2 revenue $700,000.Q2 revenue view $1.8 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Immune Design Corp - ‍based on current expectations, co continues to expect to have cash to fund operations into second half of 2018​.  Full Article

Immune Design Q1 loss per share $0.50
Wednesday, 17 May 2017 04:30pm EDT 

May 17 (Reuters) - Immune Design Corp ::Immune Design reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.50.Q1 revenue $5.5 million.Q1 revenue view $2.1 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.  Full Article

Immune Design Q4 loss per share $0.57
Tuesday, 7 Mar 2017 04:02pm EST 

Immune Design Corp : Immune design reports fourth quarter and full year 2016 financial results and provides corporate update . Q4 loss per share $0.57 . Q4 revenue $2.1 million . Q4 revenue view $1.6 million -- Thomson Reuters I/B/E/S .Q4 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
Wednesday, 28 Sep 2016 08:00am EDT 

Immune Design Corp : Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy . Trial follows exclusive license agreement with co to discover, develop, commercialize products to treat a peanut allergy using GLAAS .Has received undisclosed milestone payment for start of trial, is eligible to receive future development,commercialization milestones.  Full Article

Victory Capital Management reports 6.23 pct passive stake in Immune Design - SEC filing
Friday, 23 Sep 2016 01:25pm EDT 

Immune Design Corp :Victory Capital Management Inc reports 6.23 percent passive stake in Immune Design Corp as of July 31, 2016 - SEC filing.  Full Article

BRIEF-Ecor1 Capital reports 7.4% passive stake in Immune Design

* Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​ Source text: (http://bit.ly/2zkI4Ki) Further company coverage: